
Johnson & Johnson's stock target raised on strong oncology growth and new surgical tech launch.
Raymond James raised Johnson & Johnson's price target to $280, signaling a 10% upside from current levels. The boost follows strong Q2 revenue growth in its oncology division, which now accounts for nearly 29% of total revenues, driven by key cancer ...


